Communiqués Addex Therapeutics Ltd

Actions

ADXN

CH0029850754

Recherche biotechnologique et médicale

Marché Fermé - Swiss Exchange 17:31:52 21/08/2026			Varia. 5j.	Varia. 1 janv.
0,0350 ^CHF	-15,46%		-10,71%	-36,82%

08/07	Addex Therapeutics publie des recherches précliniques démontrant le potentiel thérapeutique de l'ADX71743 dans la régulation du sommeil et de l'éveil	CI
29/06	Actions suisses : les facteurs à suivre le 29 juin	RE

Communiqués

08/07	Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness	GL
30/06	Addex Therapeutics : Results ( 434)	PU
30/06	Addex Shareholders Approve All Resolutions at Annual General Meeting	GL
26/06	Addex Therapeutics : Quarter 1 Report ( 433)	PU
25/06	Addex Therapeutics : Quarter 1 Report (561782364078Addex Therapeutics Q1 2026 financial statements)	PU
25/06	Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	GL
22/06	Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026	GL
08/06	Addex Convenes Annual General Meeting 2026	AQ
05/06	Addex Therapeutics : Invitation ( 432)	PU
05/06	Addex Convenes Annual General Meeting 2026	GL
30/04	Addex Therapeutics : Annual Report ( 431)	PU
30/04	Addex Reports Full Year 2025 Financial Results and Provides Corporate Update	GL
30/04	Addex Reports Full Year 2025 Financial Results and Provides Corporate Update	AQ
29/04	Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model	GL
23/04	Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026	GL
21/04	Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model	GL
21/04	Addex Therapeutics : GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model	PU
03/02	Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment	GL
03/02	Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment	AQ
07/01	Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia	GL
11/12	Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.	GL
04/12	Addex Therapeutics : Quarter 3 Report ( 428)	PU
04/12	Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update	GL
04/12	Addex Therapeutics : Reports 2025 Third Quarter Financial Results and Provides Corporate Update	PU
01/12	Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025	GL